As a reminder, our commercial model is B2B, so there can be inherent ... We also shipped additional volumes of our biosimilar to Stelara to our U.S. partner during the quarter in support of ...

Health insurance company Cigna (NYSE:CI) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 14.4% year on ...

Johnson & Johnson and AbbVie are two major U.S. pharmaceutical companies with robust pipelines and global operations. Both ...

Right now Teva is trading at just 6.2x forward earnings well below the industry average of around 14x. Its EV/EBITDA multiple ...

WellSaid, the most trusted AI voice platform for businesses, today introduced expanded enterprise-level Studio features at ATD25, one of the world's largest events for learning and development (L&D) ...

The Case for J&J J&J's biggest strength is its diversified business model, which helps it to withstand ... for its multi-billion-dollar product, Stelara, and the negative impact of the Part ...

J&J’s biggest strength is its diversified business model, which helps it to withstand ... for its multi-billion-dollar product, Stelara, and the negative impact of the Part D redesign.

Blue Ridge Global, a leader in supply chain planning and inventory optimization solutions, announced today a strategic partnership with Tigertail Capital Partners ("TCP"), a private equity firm ...

Amgen launched the biosimilar version of J&J’s Stelara, Wezlana ... against a decrease of 4.7% for the industry. Our proven model does not conclusively predict an earnings beat for Amgen ...

With a market cap of $372.9 billion, Johnson & Johnson (JNJ) is a global healthcare leader with a robust and diversified business model spanning pharmaceuticals, medical technologies, and consumer ...